Abstract
A topically applied mixture containing two small interfering RNA (siRNA) molecules shows promise in protecting female mice against herpes simplex virus type 2 (HSV-2) infections, according to Judy Lieberman, director of the Division of AIDS at Harvard Medical School in Boston, Mass., and her collaborators. The goal is to develop this candidate product into a safe and effective ointment that will protect women against this virus, she says, noting: “There’s never been a topical antiviral agent approved for human use.”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
